Heptares, MorphoSys deal
MorphoSys partnered with Heptares to discover and develop antibodies targeting GPCRs. Heptares will generate stabilized receptors using its StaR technology for a set of GPCR targets selected by MorphoSys, which will then use its Ylanthia antibody library to develop therapeutic candidates. Heptares will receive upfront and research funding payments, plus a share of revenues from any licenses MorphoSys grants to the targets and antibodies. Heptares will use Ylanthia to develop and commercialize one antibody created by MorphoSys against a GPCR target selected by Heptares. MorphoSys is eligible to receive license fees, milestones and royalties on any Ylanthia antibody developed by Heptares. The partners declined to disclose financial details. ...